… Platinum-based chemotherapy plus cetuximab in head and neck cancer. … versus cetuximab
with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck …

… new cases of head and neck cancers worldwide, with … percent of head and neck cancers are
squamous cell carcinoma (… {5-FU}] plus cetuximab followed by cetuximab maintenance until …

… Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR … or metastatic head and neck squamous
cell carcinoma (HNSCC). … or metastatic squamous cell carcinoma of the head and neck …

… Currently, cetuximab associated with radiotherapy is limited to the … cetuximab efficacy in
this cancer setting are still lacking. This review focuses on the mechanisms of action of cetuximab…

… In a SCCHN patient-derived tumor xenograft (PDTX) model, we have previously … with
cetuximab induced slight tumor regression that could not be observed with ribociclib or cetuximab …

… Cetuximab has previously been tested in large randomized phase III trials for noncutaneous
squamous cell carcinomas of the head and neck … with concurrent cetuximab in cutaneous …

… with cetuximab for relapsed or metastatic squamous cell carcinoma of the head and neck
(RM- SCCHN), that would achieve an equivalent PFS with standard cetuximab and 5-FU/…

… cetuximab in patients with locoregionally advanced head and neck squamous cell
carcinoma (HNSCC; stage III-IV according to the Union for International Cancer Control TNM …

… We chose to have a cetuximab lead-in to exclude patients with cetuximab-related infusion
reaction. Patients having a cetuximab-related infusion reaction or who did not receive cycle 1 …

… Squamous cell carcinoma of the head and neck (SCCHN) is one of the most frequently
diagnosed cancers worldwide. More than half of patients diagnosed with locally advanced …